FIGURE

Figure 4

ID

ZDB-FIG-220131-123

Publication

Bu et al., 2021 - Inhibition of mTOR or MAPK ameliorates vmhcl/myh7 cardiomyopathy in zebrafish

Other Figures

All Figure Page

Back to All Figure Page

Figure 4

An F0 screen of 11 target genes in 7 known CM pathways identified mapk3 and mtor as 2 therapeutic modifier genes for VEC.

(A) Representative images of the heart area of F0 fish at 3 dpf. The black star indicates severe edema, and red stars indicate mild edema. Scale bar: 300 μm. (B) Fluorescence immunostaining images using anti-myosin heavy chain 1 (F59) in the ventricles of (from top to bottom): WT controls, vmhcl^e13/e13, vmhcl^e13/e13;mapk3^e2-MJ, and vmhcl^e13/e13;mtor^e6-MJ mutant hearts at 3 dpf. Scale bar: 2 μm; V, ventricle. (C) Kaplan–Meier survival curves of vmhcl^e13/e13 mutant fish upon mapk3 and mtor inhibition and WT controls. n = 15–17; log-rank test. (D and E) VCV (D) and percent FS (E) of the vmhcl^e13/e13 mutants after mapk3 and mtor inhibition compared to WT controls at 3 dpf. n = 7–8; data are presented as the mean ± SD; 1-way ANOVA.

Expression Data

Antibody:	Ab-F59
Fish:	myh7l^xu093/xu093 myh7l^xu093/xu093 + CRISPR2-mapk3 myh7l^xu093/xu093 + CRISPR3-mtor mapk3^xu092/xu092; myh7l^xu093/xu093 myh7l^xu093/xu093; mtor^{xu015Gt/xu015Gt}
Knockdown Reagents:	CRISPR2-mapk3 CRISPR3-mtor
Anatomical Term:	atrium sarcomere
Stage:	Protruding-mouth

Expression Detail

Antibody Labeling

Phenotype Data

Fish:	myh7l^xu093/xu093 myh7l^xu093/xu093 + CRISPR2-mapk3 myh7l^xu093/xu093 + CRISPR3-mtor mapk3^xu092/xu092; myh7l^xu093/xu093 myh7l^xu093/xu093; mtor^{xu015Gt/xu015Gt}
Knockdown Reagents:	CRISPR2-mapk3 CRISPR3-mtor
Observed In:	atrium sarcomere heart heart contraction whole organism
Stage Range:	Protruding-mouth to Days 7-13

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ JCI Insight